Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

The analyst points out that Eli Lilly’s success in this area is backed by several advantages that should help it maintain a leading position and market share in the furture. Even in Q4 2024 ...

Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

It plans to submit orforglipron for FDA approval for obesity in Q4, and for type 2 diabetes ... On the day of Eli Lilly's earnings report, CVS Health announced that its pharmacy benefit manager ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... of hedge funds that have stakes in them, as of Q4 2024. The hedge fund data was sourced from Insider Monkey ...

Eli Lilly and Company ( NYSE: LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Lucas Montarce - CFO Mike Czapar - SVP, IR ...

Wall Street futures surged after a joint statement from the US and China following tariff talks. Dow futures jumped 1,000 ...